Neurology and Neurosurgery - Global Neurology Academy

273-288 of 455

Assessing Disability in MS Patients with the SNRS and CombiWISE Tools
Assessing Disability in MS Patients with the SNRS and CombiWISE Tools
NeuroFrontiers
Assessing Disability in MS Patients with the SNRS and CombiWISE Tools
- Andrew Wilner, MD, FACP, FAAN
- Dejan Jakimovski, MD, PhD
The Alarming Shortage of ADHD Medication and Its Implications on Patients
The Alarming Shortage of ADHD Medication and Its Implications on Patients
NeuroFrontiers
The Alarming Shortage of ADHD Medication and Its Implications on Patients
Understanding the Cellular Basis for Altered Cognition in Schizophrenia
Understanding the Cellular Basis for Altered Cognition in Schizophrenia
NeuroFrontiers
Understanding the Cellular Basis for Altered Cognition in Schizophrenia
- Ashley Baker, MSN, PMHNP
- Samuel Dienel, PhD
Practices for Preventing Polypharmacy in Multiple Sclerosis
Practices for Preventing Polypharmacy in Multiple Sclerosis
NeuroFrontiers
Practices for Preventing Polypharmacy in Multiple Sclerosis
- Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
- Ahmed Z. Obeidat, MD, PhD
- Lauren Beranek, BS
From Assessment to Management: Tackling Catatonia in Schizophrenic Patients
From Assessment to Management: Tackling Catatonia in Schizophrenic Patients
NeuroFrontiers
From Assessment to Management: Tackling Catatonia in Schizophrenic Patients
- Ashley Baker, MSN, PMHNP
- Stanley N. Caroff, MD
How Alzheimer's and Lewy Body Pathology Impact CAA Risk Factors
How Alzheimer's and Lewy Body Pathology Impact CAA Risk Factors
NeuroFrontiers
How Alzheimer's and Lewy Body Pathology Impact CAA Risk Factors
- Charles Turck, PharmD, BCPS, BCCCP
- Jagan Pillai, MD, PhD
Advancements in Multiple Sclerosis: Insights from the 2024 ACTRIMS Forum
Advancements in Multiple Sclerosis: Insights from the 2024 ACTRIMS Forum
NeuroFrontiers
Advancements in Multiple Sclerosis: Insights from the 2024 ACTRIMS Forum
Exploring the Latest in MS Cognitive Rehabilitation Strategies
Exploring the Latest in MS Cognitive Rehabilitation Strategies
NeuroFrontiers
Exploring the Latest in MS Cognitive Rehabilitation Strategies
- Nancy Chiaravalloti, PhD
Visionary Insights: Assessing MS-Related Retinal Changes with Adaptive Optics
Visionary Insights: Assessing MS-Related Retinal Changes with Adaptive Optics
NeuroFrontiers
Visionary Insights: Assessing MS-Related Retinal Changes with Adaptive Optics
- Daniel Harrison, MD
Family Planning Clinical Considerations for Patients with Multiple Sclerosis
Family Planning Clinical Considerations for Patients with Multiple Sclerosis
NeuroFrontiers
Family Planning Clinical Considerations for Patients with Multiple Sclerosis
- Ashley Baker, MSN, PMHNP
- Anna A. Shah, MD
Unmet Needs in Rehabilitation Research for Multiple Sclerosis
Unmet Needs in Rehabilitation Research for Multiple Sclerosis
NeuroFrontiers
Unmet Needs in Rehabilitation Research for Multiple Sclerosis
- Robert Motl, PhD
New Guidance on Neurodevelopment Outcomes in Patients with Heart Defects
New Guidance on Neurodevelopment Outcomes in Patients with Heart Defects
Heart Matters
New Guidance on Neurodevelopment Outcomes in Patients with Heart Defects
MS Research: Using Epigenetic Clocks and Biomarkers to Assess Biological Aging
MS Research: Using Epigenetic Clocks and Biomarkers to Assess Biological Aging
NeuroFrontiers
MS Research: Using Epigenetic Clocks and Biomarkers to Assess Biological Aging
- Yinan Zhang, MD
Telehealth in MS Care: Addressing the Potential for Improvement and Concerns
Telehealth in MS Care: Addressing the Potential for Improvement and Concerns
NeuroFrontiers
Telehealth in MS Care: Addressing the Potential for Improvement and Concerns
- Marisa McGinley, DO
Addressing Healthcare Barriers in Patients with Multiple Sclerosis
Addressing Healthcare Barriers in Patients with Multiple Sclerosis
NeuroFrontiers
Addressing Healthcare Barriers in Patients with Multiple Sclerosis
Toxic Short RNAs May Cause Neuronal Cell Death in Alzheimer’s Disease
Toxic Short RNAs May Cause Neuronal Cell Death in Alzheimer’s Disease
NeuroFrontiers
Toxic Short RNAs May Cause Neuronal Cell Death in Alzheimer’s Disease
- Andrew Wilner, MD, FACP, FAAN
- Marcus E. Peter, PhD

18/11